Literature DB >> 23014266

Medical treatment of acquired nystagmus.

David Ehrhardt1, Eric Eggenberger.   

Abstract

PURPOSE OF REVIEW: This article synthesises recent findings and addresses relevant anatomy, pathophysiologic considerations, and current treatment options for common forms of acquired nystagmus including vestibular and gaze holding dysfunction. RECENT
FINDINGS: Some forms of nystagmus have relatively specific treatments, such as baclofen for periodic alternating nystagmus, and repositioning for benign paroxysmal positional vertigo. Recent studies have brought changes to many of the treatments of nystagmus variants. Additionally, other recent advances in nystagmus treatment, like the usage of 4-aminopyridine, have added potent medications to the physician's armamentarium.
SUMMARY: Nystagmus is a commonly encountered entity in clinical practice. However, evidence supported treatments are scarce. Medical treatment of nystagmus is difficult, with often limited and variable response to pharmacologic therapies. This mandates a continued re-evaluation of patients and creation of an individualized approach to this common clinical problem.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23014266     DOI: 10.1097/ICU.0b013e328358ba6e

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Optical Management Using Monovision and Yoked Prism for Acquired Strabismus and Nystagmus Secondary to a Neurodegenerative Disease.

Authors:  Sung Hee Kelly Lee; Weon Jun; Richard London
Journal:  Neuroophthalmology       Date:  2015-06-17

2.  Retrospective study of recession of four horizontal rectus muscle in periodic alternating nystagmus.

Authors:  Osamu Mimura; Hiroto Ishikawa; Naoki Kimura; Akiko Kimura; Cesar V Borlongan
Journal:  Clin Ophthalmol       Date:  2014-12-11

Review 3.  Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures.

Authors:  Samia Al Jabri; Jamie Kirkham; Fiona J Rowe
Journal:  BMC Ophthalmol       Date:  2019-02-08       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.